PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
For this "Hot Topics" event, Sara Hughes joined us to discuss data anonymisation, and Kert Viele discussed his work on the use of historical controls.
Chair and Discussant: Christine Fletcher, Amgen
Discussant: Andy Grieve, Aptiv Solutions
Speaker: Sara Hughes, GSK
Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach
Co-authors: Karen Wells, Paul McSorley and Andrew Freeman;
Pharmaceutical Statistics, Volume 13, Issue 3, Pages 179-183, May/June 2014
Abstract | Paper+ | Slides
Speaker: Kert Viele, Berry Consultants
Use of historical control data for assessing treatment effects in clinical trials
Co-authors: Scott Berry, Beat Neuenschwander, Billy Amzal, Fang Chen, Nathan Enas, Brian Hobbs, Joseph G. Ibrahim, Nelson Kinnersley, Stacy Lindborg, Sandrine Micallef, Satrajit Roychoudhury and Laura Thompson;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 41–54, January/February 2014
Abstract
| Paper+ | Slides
+ Papers available to view from 10th July 2014 to 7th August 2014.
For a flier advertising the event, please click here.
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.